Skip to main content
ALLERGY THERAPEUTICS PLC logo

ALLERGY THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AGY ISIN · GB00B02LCQ05 LEI · 213800PQ7AHK7KGVOE23 IL Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2018-02-12 Regulatory Filings
Country GB United Kingdom
Listing IL AGY

About ALLERGY THERAPEUTICS PLC

https://allergytherapeutics.com/

Allergy Therapeutics PLC is an immunology company focused on the research, development, diagnosis, and treatment of allergic disorders. The company specializes in creating therapies for allergy treatment and prevention, with a key focus on developing aluminum-free immunotherapies and allergy vaccines. These treatments aim to address the underlying cause of the allergy rather than merely managing symptoms. Leveraging its specialist expertise in immunology, the company strives to develop effective and convenient solutions to improve the quality of life for individuals with allergies.

Recent filings

Filing Released Lang Actions
Completion of recruitment in PQ Grass Ph II trial
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated 12 February 2018. The content is a brief announcement regarding the completion of recruitment for a Phase II clinical trial and provides an update on the expected data release timeline. It is clearly a news release disseminated through the London Stock Exchange's Regulatory News Service (RNS). Since it is a general, time-sensitive announcement that doesn't fit the specific criteria for Earnings Release (ER), Interim Report (IR), or Capital Update (CAP), and it is not merely announcing the publication of a larger report (which would be RPA), the most appropriate classification is the general regulatory announcement category, RNS.
2018-02-12 English
Hardman Research: Growth in a tough market
Report Publication Announcement Classification · 99% confidence The document is very short (3281 characters) and explicitly states that it is providing 'Additional information' via an 'RNS Number' (7100D) from the London Stock Exchange. The core content is a summary titled 'Hardman Research: Growth in a tough market' and it directs the reader to click a link to access the 'full report' via a PDF. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing or linking to a full report is classified as a Report Publication Announcement (RPA). Although it carries an RNS number, the primary function here is announcing the availability of external research, making RPA the most specific fit over the general RNS fallback.
2018-02-02 English
Trading Update
Earnings Release Classification · 98% confidence The document is identified by the RNS Number (4048D) and is explicitly titled a "Trading Update" for the six months ended 31 December 2017, with unaudited interim results to be announced later. It provides key financial highlights (revenues, cash position) and operational updates (pipeline progress, market share). This structure—a brief update on performance preceding the full interim report—is characteristic of an Earnings Release (ER). It is not the full comprehensive report (IR) nor is it a general announcement of a report's publication (RPA), as it contains substantive financial data itself. Since it is a periodical financial results announcement, ER is the most appropriate code. H1 2017
2018-01-31 English
Holdings in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains an 'RNS Number'. The content details changes in voting rights percentages (crossing thresholds) held by a major shareholder (Invesco Ltd.) in the issuer (Allergy Therapeutics PLC). This structure and content perfectly match the definition of a Major Shareholding Notification, which is categorized under the code MRQ in the provided schema. Although it is distributed via RNS, the specific nature of the filing (major holding disclosure) takes precedence over the general RNS fallback.
2018-01-10 English
PQ Birch Phase III trial completes recruitment
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated 09 January 2018. The content discusses a clinical trial milestone (completion of recruitment for PQ Birch Phase III) and provides commentary from the CEO. The document concludes with contact information and a note stating, 'This information is provided by RNS The company news service from the London Stock Exchange' and ends with 'END'. This structure is characteristic of a general regulatory news service announcement, which fits the definition of a Regulatory Filing (RNS) as a miscellaneous regulatory announcement that doesn't fit a more specific category like ER, CT, or DIRS.
2018-01-09 English
Group of companies' accounts made up to 2017-06-30
Regulatory Filings
2017-12-27 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.